Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01368588 · ClinicalTrials.gov registry record · Phase 3
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.
- Active
- Registry status
- Phase 3
- Development phase
- 2,592
- Enrollment target
- 20
- Study locations
NCT01368588 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by Radiation Therapy Oncology Group. The registered enrollment target is 2,592 participants, above the 605-participant average among 735 other Prostate Cancer trials with a reported enrollment target (328% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT01368588, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by Radiation Therapy Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,592 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.
Conditions Studied
Interventions
- RADIATION radiation therapy
- RADIATION Whole-pelvic radiotherapy (WPRT)
Study Locations (20)
Arizona
- Arizona Breast Cancer Specialists-Gilbert - Gilbert
- Arizona Center for Cancer Care-Peoria - Peoria
- Cancer Center at Saint Joseph's - Phoenix
- Saint Joseph's Hospital and Medical Center - Phoenix
- Arizona Breast Cancer Specialists-Phoenix - Phoenix
- Arizona Oncology-Deer Valley Center - Phoenix
- 21st Century Oncology-Scottsdale - Scottsdale
- Arizona Breast Cancer Specialists - Scottsdale
- Arizona Breast Cancer Specialists-Scottsdale - Scottsdale
- Arizona Oncology Services Foundation - Scottsdale
- Arizona Center for Cancer Care-Surprise - Surprise
- Arizona Oncology Associates-West Orange Grove - Tucson
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Alabama
- University of South Alabama Mitchell Cancer Institute - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,592 participants |
| Start Date | 2011-07 |
| Est. Completion | 2031-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01368588
The ClinicalTrials.gov registry entry for NCT01368588 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 2,592 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 605-participant average among 735 other Prostate Cancer trials with a reported enrollment target (328% higher). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which radiation therapy is the first listed.
NCT01368588 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Alaska, Alabama.
Frequently Asked Questions
What is clinical trial NCT01368588 about?
NCT01368588 is a clinical study titled "Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiat...
What is the current status of trial NCT01368588?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,592 participants. The study started on 2011-07. Estimated completion is 2031-07.
What conditions does trial NCT01368588 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01368588?
The interventions under investigation include: radiation therapy (RADIATION), Whole-pelvic radiotherapy (WPRT) (RADIATION).
Who is sponsoring clinical trial NCT01368588?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01368588 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.